NeoGenomics (NEO) Tops Q2 EPS by 3c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Needham Reiterates Buy Rating on Neogenomics (NEO)
July 30, 2024 6:04 AM EDTNeedham analyst Mike Matson reiterated a Buy rating and $19.00 price target on Neogenomics (NASDAQ: NEO).
The analyst comments "NEO's 2Q24 revenue and EBITDA beat consensus and management raised 2024 revenue and EBITDA guidance. Revenue growth slowed to 12% Y/Y in 2Q24 from 14% in 1Q24,... More
